Named on one round in the feed.
Since 2026-04-13
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Neomorph Neomorph develops molecular glue degraders to target and destroy disease-causing proteins. | Series B Verified against 2 sources[ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $100M | 2026-04-13 | [ PART ] |
No sector on record.